Am J Cancer Res 2012;2(1):45-64
Review Article
TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the
bone microenvironment
Gaëlle Picarda, Valérie Trichet, Stéphane Téletchéa, Dominique Heymann, Françoise Rédini
INSERM, UMR 957, Nantes, France ; Université de Nantes, Nantes Atlantique Universités, Laboratoire de Physiopathologie de la
Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, EA3822, Nantes, France.
Received September 15, 2011; accepted September 30, 2011; Epub October 9, 2011; Published January 1, 2012
Abstract: Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL/TNFSF10) has been reported to specifically induce
malignant cell death being relatively nontoxic to normal cells. Since its identification 15 years ago, the antitumor activity and
therapeutic value of TRAIL have been extensively studied. Five receptors quickly emerged, two of them being able to induce
programmed cell death in tumor cells. This review takes a comprehensive look at this ligand and its receptors, and its potential
role in primary bone tumors (osteosarcoma and Ewing’s sarcoma) therapy. The main limit of clinical use of TRAIL being the
innate or acquired resistance mechanisms, different possibilities to sensitize resistant cells are discussed in this review,
together with the impact of bone microenvironment in the regulation of TRAIL activity. (AJCR0000088).
Keywords: Tumor Necrosis Factor-Related Apoptosis Inducing Ligand, TRAIL/TNFSF10, receptor, signalingbone tumor,
microenvironment
Full Text PDF
Address all correspondence to:
Dr. Françoise Rédini
INSERM UMR957 – EA3822, Physiopathologie de la Résorption osseuse et Thérapie des Tumeurs osseuses primitives
Faculté de médecine. 1 rue Gaston Veil. 44035 Nantes cedex 1. France.
Tel : +33 (0)2 40 41 28 42 ; Fax : +33 (0) 2 40 41 28 60
E-mail : francoise.redini@univ-nantes.fr
Review Article
TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the
bone microenvironment
Gaëlle Picarda, Valérie Trichet, Stéphane Téletchéa, Dominique Heymann, Françoise Rédini
INSERM, UMR 957, Nantes, France ; Université de Nantes, Nantes Atlantique Universités, Laboratoire de Physiopathologie de la
Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, EA3822, Nantes, France.
Received September 15, 2011; accepted September 30, 2011; Epub October 9, 2011; Published January 1, 2012
Abstract: Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL/TNFSF10) has been reported to specifically induce
malignant cell death being relatively nontoxic to normal cells. Since its identification 15 years ago, the antitumor activity and
therapeutic value of TRAIL have been extensively studied. Five receptors quickly emerged, two of them being able to induce
programmed cell death in tumor cells. This review takes a comprehensive look at this ligand and its receptors, and its potential
role in primary bone tumors (osteosarcoma and Ewing’s sarcoma) therapy. The main limit of clinical use of TRAIL being the
innate or acquired resistance mechanisms, different possibilities to sensitize resistant cells are discussed in this review,
together with the impact of bone microenvironment in the regulation of TRAIL activity. (AJCR0000088).
Keywords: Tumor Necrosis Factor-Related Apoptosis Inducing Ligand, TRAIL/TNFSF10, receptor, signalingbone tumor,
microenvironment
Full Text PDF
Address all correspondence to:
Dr. Françoise Rédini
INSERM UMR957 – EA3822, Physiopathologie de la Résorption osseuse et Thérapie des Tumeurs osseuses primitives
Faculté de médecine. 1 rue Gaston Veil. 44035 Nantes cedex 1. France.
Tel : +33 (0)2 40 41 28 42 ; Fax : +33 (0) 2 40 41 28 60
E-mail : francoise.redini@univ-nantes.fr
| AJCR Copyright © 2010-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
 | |  | |  | |  | |  | |  | |  | |  |
American Journal of Cancer Research
| ISSN: 2156-6976 |